Screening and identification of key biomarkers associated with amyotrophic lateral sclerosis and depression using bioinformatics
Four codes account for most dysphagia rejections across gastroenterology, neurology, and speech pathology billing
No se ha completado ningn ensayo clnico de fase III en humanos hasta la fecha la mayora de los datos provienen de modelos animales
received advisory/consulting fees and/or other support from Altimmune, AstraZeneca, Bayer, Biomea, Boehringer Ingelheim, Carmot Therapeutics, Cytoki Pharma, Eli Lilly, Intercept, Janssen/Johnson & Johnson, Mannkind, Mediflix, Merck, Metsera, Novo Nordisk, Pharmaventures, Pfizer, Regeneron, Sanofi, Shionogi, Structure Therapeutics, Target RWE, Terns Pharmaceuticals, The Comm Group, Valeritas, WebMD and Zealand Pharma